CNP and type 1 diabetes mellitus: Niaspan alone, and combination of BMSC+Niaspan, treatment all significantly increased NG2, CNPase, Synaptophysin, and SMI-31 (A–E) expression compared to T1DM-MCAo control; While combination treatment also additively increased CNPase, Synaptophysin and SMI-31 (C–E) expression when compared to BMSC monotherapy.